AUTL: Autolus Pharma Net earnings per share (EPS TTM)

Public company logo of Autolus Therapeutics PLC (AUTL)

Risks for Autolus Therapeutics (AUTL) are linked to biomaterial logistics and product scaling rates, as evidenced by the trailing 12-month earnings per share, where the value of -0.97 serves as the current metric. Stability is ensured by The Nucleus, the company's own manufacturing facility in Britain. The strategy is based on creating programmable T-cells for leukemia treatment and reducing costs through production automation.

AUTL (Autolus Therapeutics) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/14/2026

Autolus Therapeutics - analytical breakdowns and key metrics (AUTL)

- share price and expert price forecast:
Stock Quotes Autolus Therapeutics plc|AUTL - Fair Value Consensus
- market capitalization information:
Market Capitalization Autolus Corp|AUTL - Real Price to Acquire Entire Company
- business book valuation details:
Book Value per Share Autolus Therapeutics|AUTL - Total Stockholders' Equity|Market Value to Book Value Ratio autolus.com|AUTL - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Autolus Therapeutics|AUTL - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Autolus Therapeutics|AUTL - Aggregate Debt Obligations|Debts to Book Capitalization Autolus Pharma|AUTL - Long-Term Indebtedness|Company Short-Term Debts Autolus Therapeutics|Quick Liquidity autolus.com
- net income and valuation multiples indicators:
AUTL - Company Profit|Projected Future Earnings Autolus Therapeutics|AUTL - Market Cap to Earnings|Projected Price to Earnings Autolus Pharma|AUTL - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Autolus Therapeutics plc|AUTL - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Autolus Therapeutics|AUTL - Earnings per share for the trailing year|Quarterly EPS earnings growth autolus.com|AUTL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Autolus Therapeutics
- revenue and sales proceeds data:
AUTL - Company Sales Revenue|Projected Sales Volume autolus.com|AUTL - P/S Multiple|Price-to-Projected Revenue Ratio Autolus Therapeutics PLC
General company analysis:autolus.com (AUTL)
Mass-produced product of Autolus Corp

This metric measures actual business efficiency by dividing total annual net income by the total number of shares to evaluate the earnings per share. Analyzing the rolling 12-month EPS allows for tracking the impact of CAR-T therapy manufacturing complexities and insurance reimbursement challenges on the bottom-line profitability of Autolus Therapeutics (AUTL), signaling the company's ability to generate value amidst fierce competition.

Analysis of competing companies

LEGN: Net earnings per share for the last 12 months|Earnings per share for the trailing year SANA (Sana Biotechnology, Inc.)|ALLO: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Cartesian Therapeutics Inc|CLLS (Cellectis SA) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months cariboubio.com CRBU|Earnings per share for the last twelve months Instil Bio (TIL)|Earnings per share for the last twelve months GNTA (Genenta Science SpA)|Earnings per share for the last twelve months Century Therapeutics Inc IPSC|jaspertherapeutics.com - Earnings per share for the last twelve months|SNTI: Net earnings per share for the last 12 months|Earnings per share for the trailing year ADAP (adaptimmune.com)|CERO: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Alaunos Therapeutics Inc. TCRT|ACHL (Achilles Therapeutics PLC) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months CARGO Therapeutics, Inc CRGX|Earnings per share for the last twelve months Poseida Therapeutics, Inc. (PSTX)|2seventy bio, Inc. - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) GRCL (Gracell)